Collaborative Working Project between Leeds Teaching Hospitals NHS Trust and Pfizer Limited
Developing and co ordinating clinical pathways to review and optimise the diagnosis and treatment of patients with a suspected or confirmed diagnosis of cardiac amyloidosis across North & West Yorkshire.
Cardiac Amyloidosis (CA) is a progressive infiltrative heart muscle disease, caused by the accumulation of insoluble amyloid fibrils in the heart muscle (myocardium). The resulting cardiomyopathy eventually progresses to end-stage heart failure. Life expectancy without access to specialised treatment is poor.
This project is aimed at supporting, via a collaborative working agreement between the Leeds Teaching Hospitals NHS Trust (LTHT) and Pfizer UK Ltd., the delivery of a comprehensive plan to educate, improve disease awareness, develop operational capabilities and understand and deliver patient focused services with equity, all targeted at improving clinical pathways across West Yorkshire and North Yorkshire.
The project will fund the provision of a Clinical Fellow working in the Heart Failure Service and Heart Muscle Disease Clinic to support the care of patients with cardiac amyloidosis. This approach aims to ensure that there is a thorough and coordinated clinical pathway to assess cardiac amyloidosis patients through local multidisciplinary teams (MDT) and ensure access to diagnostics and licensed treatments in a timely manner.
To improve the care of patients with cardiac amyloidosis by improving awareness, education, equity of access and clinical pathways across the North & West Yorkshire areas.
Leeds Teaching Hospitals NHS Trust will contribute:
Pfizer UK Ltd will contribute:
-
Clinical Fellow funding: £93,583.00
-
Human resource support: 150 hours £5,250.00